Saad J. Kenderian, MB, CHB, consultant, discusses the safety and efficacy findings derived from the phase 1/2 TRANSCEND CLL 004 study in CLL/SLL.
Saad J. Kenderian, MB, CHB
Advertisement
Articles by Saad J. Kenderian, MB, CHB
Saad J. Kenderian, MB, CHB, discusses ongoing research taking place to potentially move liso-cel into earlier lines of therapy for patients with CLL.
Saad J. Kenderian, MD, CHB, discusses the FDA approval of lisocabtagene maraleucel for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Advertisement
Latest Updated Articles
Dr Kenderian on Moving Liso-Cel to the First Line of CLL TreatmentPublished: March 28th 2024 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5